Cargando…
Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study
Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbiditie...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675806/ https://www.ncbi.nlm.nih.gov/pubmed/38005858 http://dx.doi.org/10.3390/v15112180 |
_version_ | 1785141152426491904 |
---|---|
author | De Vito, Andrea Moi, Giulia Saderi, Laura Puci, Mariangela V. Colpani, Agnese Firino, Laura Puggioni, Anna Uzzau, Sergio Babudieri, Sergio Sotgiu, Giovanni Madeddu, Giordano |
author_facet | De Vito, Andrea Moi, Giulia Saderi, Laura Puci, Mariangela V. Colpani, Agnese Firino, Laura Puggioni, Anna Uzzau, Sergio Babudieri, Sergio Sotgiu, Giovanni Madeddu, Giordano |
author_sort | De Vito, Andrea |
collection | PubMed |
description | Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbidities and risk factors might affect the impact of vaccines and antiviral treatments. To this end, we aimed to evaluate and disentangle the impact of anti-SARS-CoV-2 treatments and that of underlying clinical factors associated with a shortened length of SARS-CoV-2 infection. Hence, we recorded the timeframe of positive nasopharyngeal swab in people infected while being hospitalized for reasons other than SARS-CoV-2 infection. All patients who died or were discharged with a positive swab were excluded from the study. A total of 175 patients were included in this study. Clinical conditions encompass malignancies, immunological disorders, cardiovascular, metabolic, neurodegenerative, and chronic kidney disease. Most of the participants (91.4%) were vaccinated before admission to the hospital, and 65.1% received antiviral treatment within three days after the symptom’s onset. Unvaccinated patients had a longer median time to negativity than people who received at least two doses of vaccine (18 vs. 10 days). Concerning the clinical conditions of all patients, multivariate analysis highlighted a lower probability of 14-day conversion of antigenic test positivity in patients with hematological malignancy, including those vaccinated and those exposed to antiviral therapies. In conclusion, our data showed that prompt administration of antiviral treatments accelerates the clearance of SARS-CoV-2. Further, in the elderly patients under study, previous vaccination and antiviral treatment synergize to reduce time to negativity. This translates into a shorter hospitalization time and a lower risk of transmission through patients and connected healthcare workers in a hospital ward setting, with considerable improvement in cost-effective care management. |
format | Online Article Text |
id | pubmed-10675806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106758062023-10-30 Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study De Vito, Andrea Moi, Giulia Saderi, Laura Puci, Mariangela V. Colpani, Agnese Firino, Laura Puggioni, Anna Uzzau, Sergio Babudieri, Sergio Sotgiu, Giovanni Madeddu, Giordano Viruses Article Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbidities and risk factors might affect the impact of vaccines and antiviral treatments. To this end, we aimed to evaluate and disentangle the impact of anti-SARS-CoV-2 treatments and that of underlying clinical factors associated with a shortened length of SARS-CoV-2 infection. Hence, we recorded the timeframe of positive nasopharyngeal swab in people infected while being hospitalized for reasons other than SARS-CoV-2 infection. All patients who died or were discharged with a positive swab were excluded from the study. A total of 175 patients were included in this study. Clinical conditions encompass malignancies, immunological disorders, cardiovascular, metabolic, neurodegenerative, and chronic kidney disease. Most of the participants (91.4%) were vaccinated before admission to the hospital, and 65.1% received antiviral treatment within three days after the symptom’s onset. Unvaccinated patients had a longer median time to negativity than people who received at least two doses of vaccine (18 vs. 10 days). Concerning the clinical conditions of all patients, multivariate analysis highlighted a lower probability of 14-day conversion of antigenic test positivity in patients with hematological malignancy, including those vaccinated and those exposed to antiviral therapies. In conclusion, our data showed that prompt administration of antiviral treatments accelerates the clearance of SARS-CoV-2. Further, in the elderly patients under study, previous vaccination and antiviral treatment synergize to reduce time to negativity. This translates into a shorter hospitalization time and a lower risk of transmission through patients and connected healthcare workers in a hospital ward setting, with considerable improvement in cost-effective care management. MDPI 2023-10-30 /pmc/articles/PMC10675806/ /pubmed/38005858 http://dx.doi.org/10.3390/v15112180 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Vito, Andrea Moi, Giulia Saderi, Laura Puci, Mariangela V. Colpani, Agnese Firino, Laura Puggioni, Anna Uzzau, Sergio Babudieri, Sergio Sotgiu, Giovanni Madeddu, Giordano Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title | Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title_full | Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title_fullStr | Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title_full_unstemmed | Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title_short | Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study |
title_sort | vaccination and antiviral treatment reduce the time to negative sars-cov-2 swab: a real-life study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675806/ https://www.ncbi.nlm.nih.gov/pubmed/38005858 http://dx.doi.org/10.3390/v15112180 |
work_keys_str_mv | AT devitoandrea vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT moigiulia vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT saderilaura vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT pucimariangelav vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT colpaniagnese vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT firinolaura vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT puggionianna vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT uzzausergio vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT babudierisergio vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT sotgiugiovanni vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy AT madeddugiordano vaccinationandantiviraltreatmentreducethetimetonegativesarscov2swabareallifestudy |